PCKS9 inhibitors lower cholesterol and don’t have the same types of side effects as statins. However, there is no evidence that they decrease heart attacks and strokes the way statins do. PCSK9 inhibitors come with a very high price tag (about $15,000 per year). Some insurance companies, including Medicare, pay for the drug when treatment with statins is either inadequate or causes adverse effects. But it takes time to prove that a statin isn’t effective for an individual.
To continue reading this article, you must login
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.